Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453804
Status:
COMPLETED
Last Update Posted:
2008-03-18
First Post:
2007-03-27
Brief Title:
Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness SMI
Sponsor:
State University of New York - Upstate Medical University
Organization:
State University of New York - Upstate Medical University
Study Overview
Official Title:
Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness SMI A Pilot Study
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
vivitrol
Brief Summary:
The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence Secondary aims include providing a preliminary assessment of the tolerability and safety of long-acting injectable naltrexone as compared with oral naltrexone in patients with SMI who also have a diagnosis of alcohol dependence An additional aim is to provide a preliminary assessment of the efficacy of long-acting injectable naltrexone as compared with oral naltrexone in reducing alcohol use from baseline levels
Detailed Description:
The overall goal of this project is to improve the treatment of alcohol abuse and dependence in patients with serious mental illness SMI SMI for this study is defined as any patient with any of the following diagnoses schizophrenia schizoaffective disorder bipolar type I disorder major depressive disorder with psychotic features or psychotic disorder not otherwise specified Alcohol and other substance use disorders SUDs are common among individuals with SMI such as schizophrenia SUD comorbidity is associated with many adverse consequences However to date few reports have addressed the efficacy of pharmacological treatments for SUDs in this population Naltrexone pharmacotherapy is an effective treatment for alcohol dependence but it has not been systematically applied to the care of patients with SMI This pilot study plans to use a new intramuscular long-acting form of naltrexone that needs to be administered every 4 weeks compared to daily oral naltrexone which we are also studying in this pilot This could improve adherence to a medication regimen which has been shown to be critical to successful naltrexone treatment of alcohol dependence The proposed project is a 1-year pilot program of research It is a randomized prospective parallel groups open-label trial of long-acting intramuscular IM naltrexone injected every 4 weeks compared to monthly prescriptions of oral naltrexone in a cohort of 20 subjects ten for each treatment modality The study is 16 weeks in duration consisting of a 12-week course of naltrexone plus one follow-up interview at 4 weeks after discontinuation of medication Voucher-based incentives are provided to all subjects to ensure attendance for medication administration Weekly motivational counseling sessions are conducted and focus on improving motivation to stop alcohol use Study outcomes consist of self-report and biological measures of alcohol use as well as measures of psychiatric symptom severity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None